BY ALBERT RONNING-ANDERSSON
-
Abbott makes major investment in cancer screening – pays USD 23bn for US diagnostics company
The acquisition ranks among the top five largest within medtech and diagnostics in recent times, says Claus Henrik Johansen, CEO of the investment association Global Health Invest.
-
WSA CEO confident in US comeback despite significant decline
The Danish hearing health and wellness team is spending greatly in the sales network for insurance-aided therapy with listening devices in the United States, yet this sales network…
-
Genmab scraps another asset from last year’s billion-dollar acquisition of Profoundbio: “It’s not a major blow”
In September, when the advancement of one more property was stopped, the firm ensured that it would certainly proceed servicing the various other medication prospects from the purc…
-
Novo Holdings sells all shares in British Convatec
In 2017, Novo Holdings obtained simply under 20% of the shares in Convatec for about DKK 8.7 bn. Currently, the mutual fund is offering every one of its staying shares for much les…
-
GN tightens recruitment: “We ask a few more questions than before”
At the start of the year, the listening devices team introduced a cost-cutting program, which has actually not brought about discharges, according to the chief executive officer.
-
GN postpones profit target for US online store
GN had actually formerly intended to go back to earnings by the end of 2025 or very early 2026, yet the timeline has actually currently been pressed back by a year because of damag…
-
Top executives in Danish life science companies under mounting pressure: Employment periods are plummeting
The period of magnates in the Danish pharmaceutical sector has actually dropped by roughly 50% over the previous 20 years, according to brand-new numbers.
-
After a futile battle, Biomarin will sell the bleeding disorder drug Roctavian
The United States business is checking out choices to unload Roctavian from its profile after 2 unstable years given that the hemophilia A genetics treatment was accepted.
-
Investor on Novo’s attempt to take over Pfizer’s billion-dollar deal: Could sweep competitor off the field
If Novo Nordisk does well in getting the biotech business Metsera, the Danish business will certainly have one much less significant rival to emulate in the important excessive wei…
-
Catalent lays off 350 at US plant
The United States agreement supplier was gotten by Novo Holdings in 2014 in the biggest company handle Danish background.
